Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Manidipine 6300. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Manidipine 6300 SCHEMBL247471 | 0.98 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL29801590 | 0.98 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL49368 | 0.98 | MAPT (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL28185730 | 0.98 | MAPT (0.69) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL6275097 | 0.98 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL247919 | 0.98 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137616 | 0.98 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL1491200 | 0.98 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL137617 | 0.98 | ADRA1A (0.71) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Manidipine 6300 SCHEMBL1491189 | 0.97 | ADRA1A (0.70) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250003952-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | KYOTO UNIVERSITY (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4400117-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | Kyoto University (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024135719-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | 国立大学法人京都大学 | 2024-06-27 | — | — | WO | disclosed |
| CN-117915953-A | Method for screening senescent cell scavenger and senescent cell scavenger | 国立大学法人京都大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | disclosed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| CN-116600799-A | Pharmaceutical combination for the treatment and/or prophylaxis of diabetes | 银丝佛若有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023038027-A1 | SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG | 国立大学法人京都大学 | 2023-03-16 | — | — | WO | disclosed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | CACNA1C 2966/4885MAPT 2266/4885CYP1A2 4835/4885 |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | CACNA1C 5/4885MAPT 2707/4885CYP1A2 3472/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CACNA1C 901/4885MAPT 1763/4885CYP1A2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.